Although neoadjuvant pertuzumab has been used as the standard of care for patients with locally advanced HER2-positive breast cancer, our study suggests that pyrotinib can be a novel option for patients who cannot use pertuzumab possibly due to low tolerance or high price [33]. Here, ERBB2 is linked to breast carcinoma.